FOXP3 and myeloid sarcoma: miR-223 significantly upregulated in CD4+T-cells during the relapsing phase ofRR-MS compared to the remitting phase (P=0.000) and healthy individuals (P=0.036).Expression of RORγt, a master transcription factor of Th17, upregulated in the relapsing phase, whereas FOXP3 upregulated in the remitting phase.